These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 33886044)

  • 1. Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes.
    Matza LS; Cutts KN; Stewart KD; Norrbacka K; García-Pérez LE; Boye KS
    Qual Life Res; 2021 Jul; 30(7):2033-2043. PubMed ID: 33886044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient preferences and health state utilities associated with dulaglutide and semaglutide injection devices among patients with type 2 diabetes in Italy.
    Boye KS; Matza LS; Stewart KD; Jordan J; Biricolti G; Del Santo S; Perez-Nieves M; Federici MO; Gentilella R; Losi S; Norrbacka K
    J Med Econ; 2019 Aug; 22(8):806-813. PubMed ID: 31010349
    [No Abstract]   [Full Text] [Related]  

  • 3. Health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes.
    Matza LS; Boye KS; Stewart KD; Davies EW; Paczkowski R
    BMC Health Serv Res; 2017 Nov; 17(1):774. PubMed ID: 29178918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preference for Oral and Injectable GLP-1 RA Therapy Profiles in Japanese Patients with Type 2 Diabetes: A Discrete Choice Experiment.
    Igarashi A; Bekker Hansen B; Langer J; Tavella F; Collings H; Davies N; Wyn R
    Adv Ther; 2021 Jan; 38(1):721-738. PubMed ID: 33245530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia.
    Malkin SJP; Russel-Szymczyk M; Psota M; Hlavinkova L; Hunt B
    Adv Ther; 2019 Aug; 36(8):2034-2051. PubMed ID: 31168765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient preferences in Italy: health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes.
    Matza LS; Boye KS; Jordan JB; Norrbacka K; Gentilella R; Tiebout AR; Browne C; Orsini Federici M; Biricolti G; Stewart KD
    Patient Prefer Adherence; 2018; 12():971-979. PubMed ID: 29922043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy.
    Wright EE; Aroda VR
    Postgrad Med; 2020 Nov; 132(sup2):26-36. PubMed ID: 32815423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular safety outcomes of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.
    Goldman JD
    J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):61-72. PubMed ID: 32910492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER).
    Matza LS; Boye KS; Stewart KD; Coyne KS; Wullenweber PK; Cutts KN; Jordan JB; Wang Q; Yu M; Currie BM; Malley KG; Ishak KJ; Hietpas RT; García-Pérez LE
    Diabetes Obes Metab; 2020 Mar; 22(3):355-364. PubMed ID: 31646727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patients' preferences for once-daily oral versus once-weekly injectable diabetes medications: The REVISE study.
    Boye K; Ross M; Mody R; Konig M; Gelhorn H
    Diabetes Obes Metab; 2021 Feb; 23(2):508-519. PubMed ID: 33140575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New drug for type 2 diabetes: introduction of oral Semaglutide (Rybelsus
    Miyasaka K
    Nihon Yakurigaku Zasshi; 2022; 157(2):146-154. PubMed ID: 35228448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycaemic and non-glycaemic efficacy of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.
    Patel D
    J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):28-42. PubMed ID: 32910489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.
    Pieber TR; Bode B; Mertens A; Cho YM; Christiansen E; Hertz CL; Wallenstein SOR; Buse JB;
    Lancet Diabetes Endocrinol; 2019 Jul; 7(7):528-539. PubMed ID: 31189520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands.
    Hunt B; Malkin SJP; Moes RGJ; Huisman EL; Vandebrouck T; Wolffenbuttel BHR
    BMJ Open Diabetes Res Care; 2019; 7(1):e000705. PubMed ID: 31641522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Dulaglutide and Sitagliptin in the Spanish Setting.
    Martín V; Vidal J; Malkin SJP; Hallén N; Hunt B
    Adv Ther; 2020 Oct; 37(10):4427-4445. PubMed ID: 32862365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preferences of patients with diabetes mellitus for inhaled versus injectable insulin regimens.
    Chancellor J; Aballéa S; Lawrence A; Sheldon R; Cure S; Plun-Favreau J; Marchant N
    Pharmacoeconomics; 2008; 26(3):217-34. PubMed ID: 18282016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient preferences and health state utilities associated with the treatment process of antiretroviral therapy for people living with HIV.
    Matza LS; Howell TA; Chounta V; van de Velde N
    Qual Life Res; 2023 Feb; 32(2):531-541. PubMed ID: 36512302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?
    Gentilella R; Pechtner V; Corcos A; Consoli A
    Diabetes Metab Res Rev; 2019 Jan; 35(1):e3070. PubMed ID: 30156747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost-effectiveness of once-weekly semaglutide compared with other GLP-1 receptor agonists in type 2 Diabetes: a systematic literature review.
    Ruan Z; Yang L; Shi H; Yue X; Wang Y; Liang M; Hu H
    Expert Rev Pharmacoecon Outcomes Res; 2021 Apr; 21(2):221-233. PubMed ID: 33317348
    [No Abstract]   [Full Text] [Related]  

  • 20. Disutility of injectable therapies in obesity and type 2 diabetes mellitus: general population preferences in the UK, Canada, and China.
    McEwan P; Baker-Knight J; Ásbjörnsdóttir B; Yi Y; Fox A; Wyn R
    Eur J Health Econ; 2023 Mar; 24(2):187-196. PubMed ID: 35526173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.